Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647938 | 0.91 | ALDH1A1 (0.70) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL1042604 | 0.89 | KMT2A (0.60) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL19392289 | 0.89 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL12651867 | 0.89 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL12509821 | 0.89 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL1041595 | 0.88 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL108732 | 0.87 | POLB (0.69) | ALDH1A1DPP7KDM4EKMT2AMEN1 | |
| SCHEMBL25990229 | 0.86 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL7392627 | 0.86 | DPP7 (0.62) | ALDH1A1L3MBTL1DPP7KDM4ETSHR | |
| SCHEMBL19326697 | 0.86 | DPP7 (0.62) | ALDH1A1L3MBTL1DPP7KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260148-B | Compound extracted and separated from long pepper and application of compound in preparation of anti-inflammatory drugs | 中南民族大学 | 2023-05-05 | — | — | CN | claimed |
| CN-115260148-A | Compound extracted and separated from long pepper and application of compound in preparation of anti-inflammatory drugs | 中南民族大学 | 2022-11-01 | — | — | CN | claimed |
| CN-115260148-B | Compound extracted and separated from long pepper and application of compound in preparation of anti-inflammatory drugs | 中南民族大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-115260148-A | Compound extracted and separated from long pepper and application of compound in preparation of anti-inflammatory drugs | 中南民族大学 | 2022-11-01 | — | — | CN | disclosed |
| EP-3024458-A1 | USE OF FLECAINIDE AS AN ANTI-CONNEXIN AGENT AND METHOD FOR POTENTIATING THE EFFECTS OF A PSYCHOTROPIC DRUG | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015011246-A1 | USE OF FLECAINIDE AS AN ANTI-CONNEXIN AGENT AND METHOD FOR POTENTIATING THE EFFECTS OF A PSYCHOTROPIC DRUG | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-01-29 | — | — | WO | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1480941-A2 | UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2004-12-01 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003074467-A2 | UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-09-12 | — | — | WO | disclosed |
| US-6528532-B1 | Benzenesulfonamide group | PHARMACOR INC. (CA) | 2003-03-04 | — | — | US | disclosed |
| US-6143917-A | FROM A DIARYL CARBONATE AND AN AMINE COMPOUND HAVING AT LEAST ONE HYDROGEN ATOM LOCATED AT AN N-POSITION UNDER MODERATE CONDITIONS AT A HIGH REACTION RATE WITH A HIGH SELECTIVITY AND WITH A HIGH YIELD | UBE INDUSTRIES, LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0902014-A1 | PROCESS FOR PRODUCING ARYL CARBAMATES | UBE INDUSTRIES LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |